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Abstract
Background: Hospitalizations for ambulatory care sensitive conditions are commonly used to evaluate primary
health care performance, as the hospital admission could be avoided if care was timely and adequate.
Previous evidence indicates that avoidable hospitalizations carry a substantial direct financial burden in some
countries. However, no attention has been given to the economic burden on society they represent. The aim
of this study is to estimate the direct and lost productivity costs of avoidable hospital admissions in Portugal.
Methods: Hospitalizations occurring in Portugal in 2015 were analyzed. Avoidable hospitalizations were
defined and their associated costs and years of potential life lost were calculated. Direct costs were obtained
using official hospitalization prices. For lost productivity, there were estimated costs for absenteeism and
premature death. Costs were analyzed by components, by conditions and by variations on estimation
parameters.
Results: The total estimated cost associated with avoidable hospital admissions was €250 million (€2515 per
hospitalization), corresponding to 6% of the total budget of public hospitals in Portugal. These hospitalizations
led to 109,641 years of potential life lost. Bacterial pneumonia, congestive heart failure and urinary tract
infection accounted for 77% of the overall costs. Nearly 82% of avoidable hospitalizations were in patients
aged 65 years or older, therefore did not account for the lost productivity costs. Nearly 84% of the total cost
comes from the direct cost of the hospitalization. Lost productivity costs are estimated to be around €40
million.
Conclusion: The age distribution of avoidable hospitalizations had a significant effect on costs components.
Not only did hospital admissions have a substantial direct economic impact, they also imposed a considerable
economic burden on society. Substantial financial resources could potentially be saved if the country reduced
avoidable hospitalizations.
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Background
Ambulatory care sensitive conditions (ACSCs) are
health conditions for which hospital admission could
be prevented by timely and adequate ambulatory care
[1, 2]. Hospitalizations for ACSCs have been exten-
sively used in health care research and health policies
to assess accessibility, quality and performance of the
primary health care, as timely and effective primary
care could potentially avoid hospitalization [3, 4].
Previous studies in the field have mostly analyzed
rates and trends of hospitalizations for ACSCs and
the association with different contextual factors; less
attention has been given to the economic and social
impact these hospitalizations produce.
Direct costs of admissions for ACSCs were esti-
mated in previous studies in Ireland [5], the United
Kingdom [6, 7], France [8] and Brazil [9, 10], using
the official prices of hospitalizations in each country’s
respective national health system. Two studies in
Portugal used different ACSC definition methodolo-
gies to estimate costs associated with avoidable hos-
pital admissions [11, 12]; the first (in 2007) used the
methodology of Agency for Healthcare Research and
Quality (AHRQ) [4], while the second (in 2014) used
the ACSC list developed by Caminal [13]. These stud-
ies found that the direct costs of avoidable hospital
admissions amounted to approximately €200 million
and €250 million, respectively. Both studies found
that around 10% of all hospitalizations in Portugal
were potentially avoidable [11, 12], indicating that
there is room for improvement in the country regard-
ing ACSCs.
Of the limited number of studies that estimated the
costs of avoidable hospitalizations, none of them in-
cluded estimations of costs for lost productivity, lost
wages and premature death. Although the findings of
existing studies already indicate that avoidable hospitali-
zations create a substantial direct financial burden on
health expenditures, considering lost productivity costs
can further illustrate how much economic pressure such
hospitalizations present.
Analysis of the economic burden on society associated
with avoidable hospitalizations provides valuable infor-
mation for planning of health services and allocation of
resources. Moreover, as such hospitalizations could have
potentially been avoided in the ambulatory care setting;
this analysis indicates the potential of saving costs by re-
ducing hospitalizations for ACSCs. The aim of this study
was to estimate direct and lost productivity costs of hos-
pitalizations for ACSCs in Portugal. This country pro-
vides universal health care, with services financed
primarily through tax payments. The primary health care
is intended to be the first point of contact of users with
the health system.
Methods
Data source and sample definition
This study used the hospitalization data base provided
by the Portuguese Central Administration of the Health
System for the year 2015. A total of 1,000,670 hospitali-
zations were registered in continental Portugal in 2015.
For each hospital admission, the inpatient data used in
this study were age, sex, principal and secondary diagno-
sis (according to ICD-9-CM code), diagnosis-related
groups (DRGs), length of stay and reason for end of the
hospitalization.
The definition of which hospitalizations were for
ACSCs was determined according to the AHRQ meth-
odology, which uses the codes of principal and second-
ary diagnosis, for different versions of the ICD [4]. This
list has a strong theoretical basis for its composition and
a well-defined methodology for inclusion of cases and
exclusion of some comorbidities [4]. The AHRQ guide-
lines provide more details in disease coding and inclu-
sion/exclusion criteria [4].
Cost estimation
The costs associated with hospitalizations for ACSCs
were both direct and from a socioeconomic perspective,
incurred by lost productivity. The identification of direct
costs was done in the total of hospitalizations. The valu-
ation was done according to the number of hospital ad-
missions classified as avoidable. For the monetization of
direct costs, official hospital inpatient admission prices
were used as proxy for costs. Prices are defined by DRGs
and severity of the condition, according to values pub-
lished by the Ministry of Health [14]. The prices corres-
pond only to the hospital admission and, therefore did
not include other pre- and post-hospitalization expenses.
Lost productivity costs were identified for absenteeism
and premature death. The valuation was based on to the
length of stay and years of potentially productive life lost
for avoidable hospitalizations. In order to monetize
productivity losses, the human capital approach was ap-
plied. In this methodology, the value to society of poten-
tially lost production (either due to absenteeism or
premature death) is estimated by market wages [15, 16].
The human capital approach has been used in the litera-
ture to estimate lost productivity costs of morbidity and/
or mortality for cancer [16–18], asthma [19], E. coli in-
fections [20], visual impairment [21] and road traffic ac-
cidents [22], to name a few.
For all hospitalizations for ACSCs, the estimated ab-
senteeism cost was estimated as the value of days of
productivity lost, calculated as the length of stay multi-
plied by the daily wage (the monthly mean wage of the
region divided by 30 days, as done by previous studies
[23–25]), taking into account whether the person was of
working age (between 18 and 64 years of age), the
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probability of the patient being part of the labor force
(based on labor force participation) and being employed
(based on the unemployment rate).
For avoidable hospitalizations in which the patient
died in the hospital, premature deaths are understood as
potentially preventable hospitalization-related deaths
that occur at working age have a cost of lost productivity
that extends to retirement age. The estimated cost of the
lost productivity for such premature death was also cal-
culated. In this case, the years of potentially productive
life lost were calculated as the difference between the
age of the patient and the retirement age (considered 65
years old), and multiplied by the annual mean local
wage. Monthly wage, unemployment and labor force
participation were specific according to the gender of
the patient for both absenteeism and premature death,
to reflect the gender differentials in the labor market.
These data were obtained at the municipal level from
Statistics Portugal (SP).
The methodology used for lost productivity costs
only accounts for the working-age population. While
it has to be acknowledged that retired people contrib-
ute to the production of the country, this was not
monetized in this study. For equity, the impact of
avoidable hospitalizations in the whole population was
taken into consideration. Therefore, this impact was
considered illness burdens instead of lost productivity
costs. Years of potential life lost (YPLL) were calcu-
lated to quantify the burden imposed on society by
avoidable hospital admissions. YPLL were calculated
to represent the non-financial impact these hospitali-
zations present. For hospitalizations that ended in
intra-hospital death, YPLL were calculated as the dif-
ference between the age of the patient and the pa-
tient’s life expectancy based on their age and gender.
The data source was SP.
Statistical analysis
Both crude and standardized hospitalization rates were
calculated. Age and sex-standardized hospitalization
rates were calculated using the direct method, taking as
a reference the 2015 European population prospect from
the United Nations Population Division [26]. Descriptive
statistics were used to present the distribution of hospi-
talizations for ACSCs by condition, age group, mean
length of stay and the share of intra-hospital deaths.
For direct, lost productivity and total costs, cost per
person and per hospitalization were calculated. For the
direct and total costs per person, the population aged 18
or over of each country was the denominator. For the
cost of lost productivity per person, the denominator
was people aged 18 to 64 years, as people aged 65 years
or older were considered not part of the workforce and
therefore did not have associated lost productivity costs.
Sensitivity analysis
Sensitivity analysis was done according to variations in
the variables retirement age and age limit, presented as
percent variation from base-case values. The retirement
age used as the base-case was 65 years, for consistency
and to facilitate comparison. Variations were made ac-
cording to the respective official retirement ages for
basic and minimum pensions in Portugal in 2015, which
was 66 years.
Some other methodologies that identify hospitaliza-
tions for ACSCs limit the inclusion of older age groups
[27, 28], as clinical complexity and increasing prevalence
of comorbidities makes classifying hospitalizations as
avoidable problematic for this population. Therefore, an-
other variation in parameters for the sensitive analysis
was to limit the definition of hospitalizations for ACSCs
to those below 75 years. Both one-way (varying one par-
ameter at a time) and multi-way (varying different pa-
rameters simultaneously) sensitivity analysis were
performed. Costs per capita according to the variation
on each parameter were also presented.
Results
Overview of hospitalizations for ACSCs
Table 1 shows an overview of hospitalizations in
Portugal. A total of 99,417 hospitalizations were attribut-
able to ACSCs, representing 10% of the total hospital ad-
missions registered in 2015. Portugal presented crude
and standardized rates of 1254 and 851 hospitalizations
for ACSCs per 100,000 adults, respectively.
Hospitalizations for ACSCs were disproportionally
concentrated in older-age groups (> 65 years), account-
ing for more than 80% of them. The mean age of pa-
tients hospitalized for ACSCs was 76 years (SD = 14.5)
and the mean length of stay was 10 days (SD = 11.2).
Women accounted for 52% of avoidable hospital admis-
sions. Around 13.5% of the hospitalizations attributable
to ACSCs ended with intra-hospital death. The most fre-
quent cause of hospital admission was pneumonia
(35.5%), followed by congestive heart failure (22.8%) and
urinary tract infections (17.1%). Avoidable hospitaliza-
tions led to 109,641 YPLL.
Costs related to hospitalizations
Table 2 presents the estimation of costs related to hospi-
talizations for ACSCs in Portugal. The total estimated
cost associated with admissions for ACSCs was €250
million. Nearly 84% of this total cost comes from the
direct cost of the hospitalization itself. Lost productivity
costs are estimated to be around €40 million. Most of
this value was due to premature death (€37.4 million).
Absenteeism corresponded to 1% of the total estimated
costs (€2.6 million). The total cost related to ACSCs cor-
responded to €31.53 per capita. This value represented
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the financial burden that was imposed on each adult in-
habitant that could potentially have been avoided if am-
bulatory care was more effective.
Table 3 details the cost of hospitalizations for each
ACSC and by gender, and YPLL. Bacterial pneumonia
accounted for a significant share of overall costs (€106
million; 41.9%), corresponding to a higher percentage
than this condition represented in number of hospitali-
zations for ACSCs (Table 1). Bacterial pneumonia had a
value of 63,905 YPLL, which is more than half of the
YPLL for all ACSCs combined. Congestive heart failure
and urinary tract infection were also important sources
of costs associated with avoidable hospital admissions.
The order in which these conditions account for total
Table 1 Overview of population age distribution, overall hospitalizations and hospitalizations for ACSCs, Portugal, 2015
Portugal
Total number of hospitalizations 1,000,670
Number of hospitalizations for ACSCs 99,417
Hospitalizations per ACSCa
Bacterial pneumonia 35,523 (35.54%)
Congestive heart failure 22,753 (22.76%)
Hypertension 1896 (1.90%)
Chronic obstructive pulmonary disease (COPD) or asthma in older adults 10,470 (10.48%)
Asthma in younger adults 265 (0.27%)
Urinary tract infection 17,704 (17.71%)
Diabetes long-term complications 4541 (4.54%)
Diabetes short-term complications 1521 (1.52%)
Uncontrolled diabetes 993 (0.99%)
Lower-extremity amputation among diabetics 1266 (1.27%)
Dehydration 3019 (3.02%)
Hospitalizations for ACSCs per total of hospitalizations 9.93%
Rate of hospitalizations for ACSCs (per 100.000 population over 18 years old) 1253.88
Age and sex-standardized rate of hospitalizations for ACSCs (per 100.000 population over 18 years old) 850.60
Hospitalizations for ACSCs per sex
Male 47,548 (47.83%)
Female 51,869 (52.17%)
Hospitalizations for ACSCs per age group
18–44 years 4455 (4.49%)
45–64 years 13,573 (13.66%)
65+ years 81,389 (81.87%)
Mean age of patients hospitalized for ACSCs (standard deviation) 75.84 (14.54)
Mean length of stay in days for hospitalizations for ACSCs (standard deviation) 10.08 (11.22)
Hospitalizations for ACSC with death outcome (% of all hospitalizations for ACSCs) 13,453 (13.53%)
Per sex and age group
Male 6732 (50.04%)
18–44 years 43 (0.32%)
45–64 years 492 (3.66%)
65+ years 6197 (46.06%)
Female 6721 (49.96%)
18–44 years 30 (0.22%)
45–64 years 194 (1.44%)
65+ years 6497 (48.29%)
Years of potential life lost 109,641
a Some discharges due to lower extremity amputation also accounted for other diabetes-related ACSC
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number of hospitalizations (Table 1) is the same as the
order of cost distribution. Dehydration and bacterial
pneumonia had the highest percentage of lost productiv-
ity representing total costs. These conditions presented
the highest mortality rates among all ACSCs.
Sensitivity analysis
Table 4 presents the results of the sensitivity analysis.
Extending the retirement age from 65 to 66 years led to
an increase of 12% on costs associated with lost product-
ivity in Portugal. The exclusion of people aged 75 years
or older had a high impact on the estimation of direct
costs, which reduced by 68%. The simultaneous variation
in both parameters led to a 55% decrease in estimated
total costs associated with hospitalizations for ACSCs. In
this case, 39.6% of total costs were due to lost
productivity.
Discussion
Key findings
Hospitalizations for ACSCs involve high costs to both
the health system and to individuals, and this situation is
cause for concern, since these episodes are potentially
avoidable. The cost of each avoidable hospitalization was
estimated at €2515 for Portugal, indicating that substan-
tial health resources could be saved by reducing the
number of avoidable hospitalizations. In 2015, the total
budget of public hospitals in Portugal was €4299 million
[29]. Avoidable hospital admissions represented 6% of
this value, indicating that they can be considered a major
source of pressure on health system resources.
This study is the first to provide estimates of lost
productivity costs associated with avoidable hospitaliza-
tions. Therefore, it is unfeasible to contrast the overall
findings of this study with the existing literature. It is
possible, however, to compare the direct costs estimated
on previous studies with the ones found here. The previ-
ous study in Portugal that also used the AHRQ method-
ology found that, between 2000 and 2007, the mean
yearly direct costs amounted to €200 million [11], which
is similar to the €210 million estimated in this study.
The previous studies in France and Ireland used DGRs.
In France, they amounted to €5066 million in 2010 [8]
(€3098 per hospitalization/ €80 per capita). In Ireland,
costs were €352 million in 2008 [5] (€5055 per
hospitalization/ €78 per capita).
It is important to emphasize that the choice of meth-
odology used to select ACSCs codes leads to differences
in the estimation of costs. The two studies in France and
Ireland used different ACSC identification methodolo-
gies that included several conditions not considered in
this study, such as vaccine-preventable conditions, an-
gina, nutritional deficiencies and cellulitis, among others
[5, 8]. The impact of differing definitions of ACSCs on
quantitative results has been pointed out by Purdy et al.
[6], in which total costs estimated in 2005 and 2006 in
England could be between £1.183 and £1.714 billion, de-
pending on the conditions considered. Furthermore,
there are possible differences in the prevalence of dis-
eases and the organization of the health care systems in
Portugal, France and Ireland. In addition, there are sub-
stantial differences between DRGs systems in European
countries [30].
The human capital approach employed in this study
attributes higher values of lost productivity to younger
people, due to the higher number of potentially product-
ive years lost. Patients over the age of 65 accounted for
81% of the 99,000 hospitalizations for ACSC. Nonethe-
less, lost productivity due to absenteeism and premature
death represented 16% of the total estimated cost. Stud-
ies produced in other countries analyzed lost productiv-
ity costs for some conditions (avoidable or not),
including diabetes [31], asthma [32], heart failure [33]
and COPD [34]. The proportion that lost productivity
accounted for total costs in these studies ranged between
15 and 47% of total costs. The results show the import-
ance of including lost productivity in cost estimation, to
represent the economic impact more comprehensively.
When comparing frequencies and costs between gen-
ders, results show that although 52% of the avoidable
hospitalizations occurred among women, they repre-
sented 46% of total costs. As each gender represented
nearly half of all intra-hospital deaths, the difference can
be seen both in the higher death rates among younger
Table 2 Estimated costs associated to hospitalizations for ACSCs, in €, 2015
Total Direct costs Lost productivity
Cost in € 250,064,177 210,026,755 40,037,422
Absenteeism Premature mortality
2,631,311 37,406,111
% of total cost 83.99% 16.01%
Cost per persona 31.53 26.49 6.83
Cost per hospitalization for ACSCa 2515.31 2112.58 2220.85
a For total and direct costs, the denominator was population over 18 years old. For lost productivity, the denominator was population between 18 and
64 years old
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age groups for men, and their higher mean salaries and
labor force participation, when compared to women.
Therefore, lost productivity was the driver for men ac-
counting for a higher share of total costs. Previous stud-
ies on costs for lost productivity for different conditions
that analyzed gender differences also found higher costs
for men [16–18].
The exclusion of people aged 75 years or older in the
sensitivity analysis showed the relevance of age distribu-
tions to the cost composition. As direct costs account
for a high share of total costs in Portugal, the estimation
of total costs in this case became less than half of what
was estimated on the base-case (from €250 million to
€68 million). Concerning the variations in the retirement
age, it is important to note that the average effective age
of retirement in different countries varies from what is
defined as official retirement age. In Portugal, there is
the possibility of retiring early or continuing to work
after retirement age. In fact, data from 2014 shows that,
among the population between 65 and 69 years in
Portugal, around 20% were still working [35].
Concerning cost distribution by condition, acute con-
ditions were responsible for more than half of all avoid-
able hospital admissions and associated costs. Previous
studies showed that distribution between avoidable con-
ditions varied substantially between countries, with dif-
ferent conditions accounting for the largest proportion
of total costs [5–8].
Strengths and limitations
To our knowledge, this is the first study to estimate both
direct and lost productivity costs associated with avoid-
able hospital admissions. Its strengths include the use of
population data and a transparent and reproducible
methodology. However, there are limitations in this
study according to the method applied to estimate costs.
The direct costs were estimated according to prices de-
fined with the purpose of reimbursing hospitals (and
therefore only cover public hospitals). These values do
not reflect actual costs of an inpatient admission. Official
prices are good proxy for real costs, are useful for health
managers as they represent values reimbursed, allow the
use of the same values for patients treated in different
hospitals but with the same disease and have been used
in other studies of cost estimation of avoidable hospitali-
zations [5, 6, 36].
When estimating lost productivity costs, the human
capital measures potential lost productivity, instead of
actual losses. The costs associated with premature death
are not limited to the year of 2015, but also include the
future lost potential such events represent. This method-
ology does not take into consideration the time it would
require to replace a worker, how long it takes for the pa-
tient to return to work after discharge and the possibility
of the patient not returning to the labor market due to
being declared permanently incapable of work. There
was no available information to calculate individually the
patients experience after the discharge, as well as no in-
dication if this population behaves the same as the aver-
age of hospitalized individuals for all causes. Costs were
estimated using a standardized 30-day month; different
approaches of estimation for daily wages provides differ-
ent results; to consider only the working days in a
month would require detailed information about the
work of the patient, which were not available. Further-
more, the estimation for premature death does not take
into consideration whether the death of the patient oc-
curred after leaving the hospital, as it could still be asso-
ciated with an ACSC. Therefore, the criteria selected
might lead to underestimation of productivity loss.
There are other methods to estimate productivity loss
costs, such as the friction cost method. The costs esti-
mated by this method are expected to be lower, as it de-
pends on the time organizations need to restore the
initial production level in the absence of a worker [37].
Estimating this time span requires lots of information on
Table 4 Sensitivity analysis results. Changes from Base-case, in %, according to different parameters on retirement age and age
exclusions
Direct cost Lost productivity Total
Base-case (in €) 210,026,755 40,037,422 250,064,177
Retirement age 0.00 + 11.81 + 1.89
Age limit
Exclusion ≥75 years −67.50 0.00 −56.69
Multi-way (retirement age and age limit) −67.50 + 11.81 −54.80
Total costs per population aged 18 years or older (in €)
Base-case 31.53
Retirement age variation 32.13
Age limit variation 13.66
Multi-way variation 14.25
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labor market conditions that was not available [38]. The
results may also change for a single country over time,
depending on the macroeconomic context [38]. The hu-
man capital approach to the estimation is grounded in
economic theory and is commonly used in the literature
of cost estimation [15, 16, 38], enhancing comparability
of results.
Conclusions
The age distribution of avoidable hospitalizations had a
significant impact on cost components in Portugal. One
of the main findings of this study was that, although
these hospital admissions had a substantial direct eco-
nomic impact, they also imposed a considerable eco-
nomic burden on society. Despite the methodological
limitations on the estimation of costs, results indicate
that substantial financial resources and YPLL could po-
tentially be saved if the country reduced hospitalizations
for ACSCs. Effective primary health care in the dimen-
sions of accessibility, prevention and promotion are im-
portant to achieve such reduction. Reducing the number
of avoidable hospitalizations can contribute to reduced
hospital care use and alleviate healthcare-related finan-
cial pressures both on the state and on society, with
positive results for the population.
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